Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Declines By 15.1%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a large drop in short interest in December. As of December 31st, there was short interest totalling 31,400 shares, a drop of 15.1% from the December 15th total of 37,000 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 25,600 shares, the short-interest ratio is presently 1.2 days.

SOPHiA GENETICS Stock Performance

Shares of SOPH traded down $0.20 during trading hours on Thursday, hitting $2.98. The stock had a trading volume of 24,505 shares, compared to its average volume of 38,600. SOPHiA GENETICS has a 12 month low of $2.70 and a 12 month high of $7.37. The stock has a fifty day moving average price of $3.29 and a 200 day moving average price of $3.69. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market capitalization of $194.83 million, a PE ratio of -2.73 and a beta of 1.00.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The firm had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. During the same quarter in the prior year, the firm earned ($0.21) earnings per share. Analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on SOPHiA GENETICS in a research report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC purchased a new position in SOPHiA GENETICS during the fourth quarter valued at $70,000. Green Alpha Advisors LLC bought a new position in shares of SOPHiA GENETICS during the 3rd quarter valued at approximately $79,000. Federated Hermes Inc. increased its holdings in SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after acquiring an additional 23,000 shares in the last quarter. Finally, Principal Financial Group Inc. raised its stake in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares during the period. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.